Your browser doesn't support javascript.
loading
Ivabradine Approved and Other Uses in Clinical Practice: A Systematic Review.
Hajiqasemi, Mohsen; Ebrahimzade, Mandana; Ghelichkhan, Zahra A; Huang, Xena; Morkos, Demyana; Jennings, Douglas; Talasaz, Azita H.
Afiliación
  • Hajiqasemi M; Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Ebrahimzade M; Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Ghelichkhan ZA; School of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran.
  • Huang X; Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Department of Pharmacy Practice, Long Island University, New York, NY.
  • Morkos D; Department of Pharmacy, New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, NY; and.
  • Jennings D; Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Department of Pharmacy Practice, Long Island University, New York, NY.
  • Talasaz AH; Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Department of Pharmacy Practice, Long Island University, New York, NY.
J Cardiovasc Pharmacol ; 84(3): 276-288, 2024 Sep 01.
Article en En | MEDLINE | ID: mdl-39027978
ABSTRACT
ABSTRACT Heart rate (HR) stands as a prognostic indicator of cardiovascular disease and a modifiable risk factor in heart failure (HF). Medication intolerance can curtail the application of conventional HR-lowering ß-blockers to the optimum target dose. Ivabradine (IVA), a specific negative-chronotropic agent, selectively inhibits I f current in pacemaker cells of the sinoatrial node without depressing myocardial contractility or comprising hemodynamics. This review summarized ivabradine's clinical labeled and off-label uses and mechanism of action focusing on the clinical outcomes. PubMed was searched up to January 2024 using the main keywords of IVA, coronary artery disease (CAD), HF, postural tachycardia syndrome (POTS), and tachyarrhythmia. To comprehensively review IVA's clinical indications, mechanisms, and therapeutic effects, all studies investigating treatment with IVA in humans were included, comprising different types of studies such as randomized controlled trials and longitudinal prospective observational studies. After screening, 141 studies were included in our review. A large number of reviewed articles were allocated to heart failure with reduced ejection fraction and CAD, suggesting IVA as an alternative to ß-blockers in case of contraindications or intolerance. The beneficial effects of IVA as premedication for coronary computed tomography angiography, HR lowering in POTS, and inappropriate sinus tachycardia constituted most studies among off-label uses. The promising results have been reported on the efficacy of IVA in controlling HR, especially in patients with inappropriate sinus tachycardia or POTS. Owing to the unique mechanism of action, IVA has the potential to be used more frequently in future clinical practice.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Cardiovasculares / Ivabradina / Frecuencia Cardíaca Límite: Animals / Humans Idioma: En Revista: J Cardiovasc Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Cardiovasculares / Ivabradina / Frecuencia Cardíaca Límite: Animals / Humans Idioma: En Revista: J Cardiovasc Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos